Reduction-rebridging strategy for the preparation of ADPN-based antibody-drug conjugates.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  MedChemComm

• Publication date

  2018-05-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c8md00141cPMID 30108971PMCID PMC6071946
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.

  2017cited by this paper
• Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.

  2017cited by this paper
• Optimisation of the dibromomaleimide (DBM) platform for native antibody conjugation by accelerated post-conjugation hydrolysis.

  2017cited by this paper
• Pyridazinediones deliver potent, stable, targeted and efficacious antibody–drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody

  2017cited by this paper
• Strategies and challenges for the next generation of antibody–drug conjugates

  2017cited by this paper
• Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates

  2016cited by this paper
• Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering

  2016cited by this paper
• Site-Specific Conjugation of Peptides and Proteins via Rebridging of Disulfide Bonds Using the Thiol-Yne Coupling Reaction.

  2016cited by this paper
• Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

  2015cited by this paper
• A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy

  2015cited by this paper
• MAPN: First-in-Class Reagent for Kinetically Resolved Thiol-to-Thiol Conjugation.

  2015cited by this paper
• Next-generation disulfide stapling: reduction and functional re-bridging all in one

  2015cited by this paper
• CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability.

  2015cited by this paper
• Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).

  2015cited by this paper
• Bridging disulfides for stable and defined antibody drug conjugates.

  2014cited by this paper
• Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

  2014cited by this paper
• Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

  2014cited by this paper
• Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

  2014cited by this paper
• Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.

  2013cited by this paper
• Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

  2004cited by this paper

• Rapid and High-Yielding Disulfide Bioconjugation at Any Desired Site in Proteins.

  2026cites this paper
• Chemotherapeutic Drug—Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions

  2025cites this paper
• Unleashing the Antiviral Potential of Stapled Peptides: A New Frontier in Combating Human Neurotropic Viral Infections

  2025cites this paper
• Unsaturated Phosphine Oxides for Modular Antibody Rebridging and Single Reagent Peptide‐Cyclization‐Bioconjugation

  2025cites this paper
• Formation of mono- and dual-labelled antibody fragment conjugates via reversible site-selective disulfide modification and proximity induced lysine reactivity

  2025cites this paper
• Site-Selective Antibody Conjugation with Dibromopyrazines

  2024cites this paper
• Chemo- and regio-selective differential modification of native cysteines on an antibody via the use of dehydroalanine forming reagents

  2024cites this paper
• Trifunctional Dibromomaleimide Reagents Built Around A Lysine Scaffold Deliver Site‐selective Dual‐modality Antibody Conjugation

  2023cites this paper
• The Nitrile Bis-Thiol Bioconjugation Reaction

  2023cites this paper
• Chemical technology principles for selective bioconjugation of proteins and antibodies.

  2023cites this paper
• Enabling the formation of native mAb, Fab′ and Fc-conjugates using a bis-disulfide bridging reagent to achieve tunable payload-to-antibody ratios (PARs)

  2023cites this paper
• Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer.

  2022cites this paper
• Bioorthogonal site-selective conjugation of fluorescent dyes to antibodies: method and potential applications

  2022cites this paper
• An overview of chemo- and site-selectivity aspects in the chemical conjugation of proteins

  2022cites this paper
• The use of bromopyridazinedione derivatives in chemical biology.

  2022cites this paper
• Divinylpyrimidine reagents generate antibody–drug conjugates with excellent in vivo efficacy and tolerability

  2022cites this paper
• All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading

  2022cites this paper
• Dual reactivity disulfide bridging reagents; enabling new approaches to antibody fragment bioconjugation

  2022cites this paper
• Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target

  2021cites this paper
• Plasmonic photothermal release of docetaxel by gold nanoparticles incorporated onto halloysite nanotubes with conjugated 2D8-E3 antibodies for selective cancer therapy

  2021cites this paper
• Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates

  2021cites this paper
• An overview of process development for antibody-drug conjugates produced by chemical conjugation technology

  2020cites this paper
• General dual functionalisation of biomacromolecules via a cysteine bridging strategy.

  2020cites this paper
• On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency

  2020cites this paper
• Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates.

  2020cites this paper
• Site-selective modification strategies in antibody-drug conjugates.

  2020cites this paper
• Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future

  2019cites this paper
• Antibody-Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents.

  2019cites this paper
• A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates† †Dedicated to Professor Jack Baldwin on the occasion of his 80th birthday. ‡ ‡Electronic supplementary information (ESI) available. See DOI: 10.1039/c

  2018cites this paper
• Homogeneous antibody-drug conjugates via site-selective disulfide bridging.

  2018cites this paper
• Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates

  2018cites this paper